Assessment of Phase 1 pharmacokinetic-pharmacodynamic predictions, based on Phase 3 clinical trials results. Depemokimab pharmacokinetics and response in blood eosinophil count reduction for asthma and chronic rhinosinusitis with nasal polyps patients